Continuous Erythropoietin Receptor Activator (Mircera) for Renal Anemia
Canadian Agency for Drugs and Technologies in Health
Record ID 32008100189
English
Details
Project Status:
Completed
URL for project:
http://cadth.ca
Year Published:
2008
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Canada
- Clinical Trials, Phase III as Topic
- Drug Approval
- Renal Dialysis
- Time Factors
- Treatment Outcome
- United States
- United States Food and Drug Administration
- Anemia
- Erythropoietin
- Kidney Diseases
- Polyethylene Glycols
- Receptors, Erythropoietin
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.